- Inoviv Pharmacy Stowal Reports on Ransomwagie Attack
- He currently restores some of his services
- Qilin ransomware operators claimed responsibility
Inov, an American pharmaceutical and biotechnological company, confirmed that it had undergone a ransomware attack which forced it to close certain parts of its computer infrastructure.
In a report to the Securities and Exchange American Commission (SEC), the company said that it had spotted the attack on August 8, 2025.
The initial investigation determined that someone intervened and encrypted “certain parts” of their systems. Inotiv then made the usual, locked the network, informing the police and using third-party security experts for forensic analysis and safety improvements.
Qilin takes the blame
However, the attack seems to have caused notable damage:
“The cybersecurity incident has caused and should continue to cause disruption of certain business operations of the company,” said Inovit in the file. “The incident has temporarily had an impact on availability and access to some of the company’s networks and systems, including access to parts of internal data storage and certain internal commercial applications.”
While working on the restoration of the services and the returning of its online systems, Inov said that it had transformed the operations impacted to “offline alternatives” to minimize the impact. There is no deadline for this and Inotiv does not seem to know when he could get back in business as usual.
Inotiv investigates the case and has not discussed the identity of the attackers. However, Bleeping Compompute I found a group of ransomware called qilin claimed responsibility, listing inov on its data leak site, saying that they have stolen from around 162,000 files which are 176 GB of size.
Samples of stolen files have also been published on the site, but at the time of the press, their authenticity has not yet been confirmed.
Inov is a contractual research organization based in the United States (CRO) which provides non-clinical and analytical drug discovery and development services for pharmaceutical and biotechnological industries. It has approximately 2,000 specialists and an annual turnover of approximately $ 500 million.
